Suzannah Lant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7589418/publications.pdf

Version: 2024-02-01

		759233	940533	
17	2,345 citations	12	16	
papers	citations	h-index	g-index	
17	17	17	5298	
17	17	17	3290	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Neurological associations of COVID-19. Lancet Neurology, The, 2020, 19, 767-783.	10.2	1,550
2	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	7.3	216
3	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	10.7	122
4	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	13.7	110
5	Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2014, 40, 686-696.	3.2	70
6	Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurology, The, 2020, 19, 826-839.	10.2	68
7	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatology, The, 2021, 3, e498-e506.	3.9	58
8	Understanding the policy dynamics of COVID-19 in the UK: Early findings from interviews with policy makers and health care professionals. Social Science and Medicine, 2020, 266, 113423.	3.8	31
9	Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design. Frontiers in Immunology, 2020, 11, 517.	4.8	31
10	Zika virus infection in the returning traveller: what every neurologist should know. Practical Neurology, 2018, 18, 271-277.	1.1	25
11	Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. PLoS ONE, 2022, 17, e0263595.	2.5	22
12	Approaches to Understanding <scp>COVID</scp> â€19 and its Neurological Associations. Annals of Neurology, 2021, 89, 1059-1067.	5. 3	16
13	Provisional case definitions for COVID-19-associated neurological disease – Authors' reply. Lancet Neurology, The, 2020, 19, 891-892.	10.2	9
14	Perspectives on COVID-19 testing policies and practices: a qualitative study with scientific advisors and NHS health care workers in England. BMC Public Health, 2021, 21, 1216.	2.9	8
15	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. Global Health Action, 2021, 14, 2008139.	1.9	5
16	Prognostic Indicators and Outcomes of Hospitalised COVID-19 Patients with Neurological Disease: A Systematic Review and Individual Patient Data Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	3
17	Bilateral median nerve neuritis after chikungunya virus infection. Lancet Infectious Diseases, The, 2020, 20, 382.	9.1	1